WaveMan
WaveMan · Company
ZOMDF · Zomedica Corp.
> Search tickers & screens ⌘K
LIVE
← All companies

ZOMDF Zomedica (ZOMDF) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001684144
Quote by TradingView
C-suite buying · 1
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
2
13F, latest reported quarter

What the filings say about ZOMDF

Insiders, 180 days
+$142.3K net bought
2 buyers

Zomedica insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Zomedica Corp. insiders bought a net $142.3K of stock across 24 Form 4 purchases and sales, with 2 insiders buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Klass Russell Kevin
Sr. Vice President, Sales
BUY
2026-05-26 SECtraded 2026-05-21
104,000
$10.4K
-20.5%
Context
  • 10 earlier Form 4 trades (code P or S) here by this insider (10 buys), the last on May 20, 2026.
  • +43.6% median (+66.8% mean) 90-day return after 8 previous buys.
  • The trade is 100.0% of the 104,000 shares held after it.
  • 1 other insider bought within 30 days.
  • 2 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Sr. Vice President, Sales Klass Russell Kevin bought about $10.4K of ZOMDF on May 21, 2026; 1 other insider bought within 30 days and 2 funds added in the latest 13F quarter.
Klass Russell Kevin
BUY
2026-05-21 SEC
5,500
$605
-20.5%
Context
  • 10 earlier Form 4 trades (code P or S) here by this insider (10 buys), the last on May 20, 2026.
  • +43.6% median (+66.8% mean) 90-day return after 8 previous buys.
  • The trade is 0.1% of the 6,001,000 shares held after it.
  • 1 other insider bought within 30 days.
  • 2 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Klass Russell Kevin bought about $605 of ZOMDF on May 21, 2026; 1 other insider bought within 30 days and 2 funds added in the latest 13F quarter.
Klass Russell Kevin
BUY
2026-05-21 SEC
11,399
$1.3K
-20.5%
Context
  • 10 earlier Form 4 trades (code P or S) here by this insider (10 buys), the last on May 20, 2026.
  • +43.6% median (+66.8% mean) 90-day return after 8 previous buys.
  • The trade is 0.2% of the 5,995,500 shares held after it.
  • 1 other insider bought within 30 days.
  • 2 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Klass Russell Kevin bought about $1.3K of ZOMDF on May 21, 2026; 1 other insider bought within 30 days and 2 funds added in the latest 13F quarter.
POWERS JOHNNY D
Director
BUY
2026-05-21 SECtraded 2026-05-20
97,515
$9.8K
-20.5%
Context
  • 7 earlier Form 4 trades (code P or S) here by this insider (7 buys), the last on May 19, 2026.
  • -21.2% median (-20.7% mean) 90-day return after 7 previous buys.
  • The trade is 2.2% of the 4,425,000 shares held after it.
  • 1 other insider bought within 30 days.
  • 2 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director POWERS JOHNNY D bought about $9.8K of ZOMDF on May 20, 2026; 1 other insider bought within 30 days and 2 funds added in the latest 13F quarter.
Klass Russell Kevin
BUY
2026-05-21 SECtraded 2026-05-20
200,000
$22.0K
-20.5%
Context
  • 9 earlier Form 4 trades (code P or S) here by this insider (9 buys), the last on Nov 13, 2025.
  • +48.8% median (+79.3% mean) 90-day return after 7 previous buys.
  • The trade is 3.3% of the 5,984,101 shares held after it.
  • 1 other insider bought within 30 days.
  • 2 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Klass Russell Kevin bought about $22.0K of ZOMDF on May 20, 2026; 1 other insider bought within 30 days and 2 funds added in the latest 13F quarter.
24 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 19 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net +$142.3K over 180 days
more than 78% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
2 funds bought in last quarter
the lowest in Pharma & Biotech
Revenue
+17.4% year over year
more than 65% of Pharma & Biotech
Margin
-255.6% net margin
below 70% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
<0.1% of the float short (float per yahoo 2026-10-27) · 1.0 days to cover · settled 2026-10-15
below 95% of Pharma & Biotech
What changed in the last 30 days
Oct 28Insider buying stopped: no purchases in 90 days after 11 in the prior 90
Why it matters
The absence is the signal: 11 purchases in one 90-day window and none in the next is a change of behaviour, not a filing.

Watch ZOMDF

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+13.3%12M
-4%+34%+73%+111%2025-102025-122026-022026-042026-062026-082026-10 2026-05-11 · POWERS JOHNNY D bought $43.0K2026-05-13 · POWERS JOHNNY D bought $22.0K2026-05-20 · Klass Russell Kevin bought $22.0K2025-11-06 · Klass Russell Kevin bought $20.2K2025-11-13 · Klass Russell Kevin bought $15.0K2025-11-10 · Klass Russell Kevin bought $12.0K2026-05-08 · POWERS JOHNNY D bought $12.0K2026-05-12 · POWERS JOHNNY D bought $11.0K2026-05-21 · Klass Russell Kevin bought $10.4K2026-05-18 · POWERS JOHNNY D bought $10.0K2026-05-20 · POWERS JOHNNY D bought $9.8K2026-05-21 · Klass Russell Kevin bought $1.3K2026-05-21 · Klass Russell Kevin bought $6052025-11-07 · Klass Russell Kevin bought $5002026-05-19 · POWERS JOHNNY D bought $248
Insider buy
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns ZOMDF: institutional holders (13F)

13F holdings, latest reported quarter
CoreCap Advisors, LLC
4,800 sh
$480
GILL CAPITAL PARTNERS, LLC
2,719 sh
$272
HARBOUR INVESTMENTS, INC.
2,200 sh
$220
EverSource Wealth Advisors, LLC
1,000 sh
$100
Bogart Wealth, LLC
680 sh
$68

Congress trades in ZOMDF

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

ZOMDF planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
Executive pay vs shareholder return · Larry Heaton
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2023
$651.4K
$1.0M
$643.2K
-13%
n/a
2022
$1.3M
-$128.9K
$732.8K
-29%
n/a
2021
$5.1M
$2.6M
$415.1K
+33%
n/a
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders are net buyers of their own stock.
The record shows a net $142.3K bought by insiders over 180 days, 2 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

ZOMDF financials

Revenue growth
+17.4%
XBRL, annual
Net margin
-255.6%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$36.9M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
-51.4%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
-$13.7M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
0.00x
LongTermDebt as filed 2021-03-31 (63 months older than the period end) (includes the current portion); equity 2026-06-30
Cash flow to debt
-25.35x
TTM operating cash flow over LongTermDebt as filed 2021-03-31 (63 months older than the period end) (includes the current portion)
Return on equity
-16.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-14.9%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on capital employed
-17.5%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$74.4M
market value at close 2026-10-27 on 2026-08-05 shares, plus LongTermDebt as filed 2021-03-31 (63 months older than the period end) (includes the current portion), minus cash 2026-06-30
FCF yield
-16.9%
TTM free cash flow over market value at close 2026-10-27
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$32.0M$27.3M$25.2M$18.9M
Gross profit$21.7M$19.1M$17.3M$13.5M
Operating income-$84.4M-$51.1M-$43.3M-$21.9M
Net income-$81.9M-$47.0M-$34.5M-$17.0M
EPS (diluted)-0.08-0.05-0.04-0.02
Operating cash flow-$17.6M-$23.6M-$16.0M-$11.7M
Cash$9.0M$7.0M$13.0M$27.4M
SEC XBRL, fiscal years, as known on 2026-10-28

ZOMDF Stock Sonar score 6/7 axes

Find similar shapesCompare

ZOMDF ranks highest on risk and compliance (97th percentile) and insider conviction (79th), and lowest on institutional and government (1st), among Pharma & Biotech peers.

ProfitHealthGrowthInsidersInstitutionsRisk
Profitability
73
Inputs
  • Return on equity-16.3% · 73 pct, sector of 545
  • Return on assets-14.9% · 71 pct, sector of 691
  • Return on invested capitalpre-tax loss, no effective tax rate to apply
  • Return on capital employed-17.5% · 75 pct, sector of 576
Financial health
49
Inputs
  • Debt to equity0.00x · 80 pct, sector of 352
  • Cash flow to debt-25.35x · 18 pct, sector of 371
Growth
65
Inputs
  • Revenue growth, YoY+17.4% · 65 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
79
Inputs
  • Net Form 4 buying (codes P and S), 180d$142K · 77 pct, sector of 429
  • Insider buyers, 180d2 · 81 pct, sector of 438
Institutional and government
0
Inputs
  • Funds adding, latest quarter2 · 0 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
97
Inputs
  • Short interest, % of float+0.0% · 97 pct, sector of 816
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
1 not measured: US patents
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

ZOMDF filings, in plain words

Are Zomedica insiders buying or selling ZOMDF?

In the 180 days to 2026-10-28, Zomedica insiders were net buyers, a net $142.3K across purchases and sales reported on Form 4, by 2 buyers.

Read the full summary

In the 180 days to 2026-10-28, Zomedica insiders were net buyers of ZOMDF, a net $142.3K across purchases and sales reported on Form 4 by 2 buyers. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies